Tech Company Financing Transactions
Stoke Therapeutics Funding Round
Stoke Therapeutics closed a $90 million Series B financing round on 10/24/2018. Backers included RTW Investments, Alexandria Venture Investments and Apple Tree Partners.
Transaction Overview
Company Name
Announced On
10/24/2018
Transaction Type
Venture Equity
Amount
$90,000,000
Round
Series B
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
3 Preston Ct. 102
Bedford, MA 01730
USA
Bedford, MA 01730
USA
Phone
Website
Email Address
Overview
Stoke (Nasdaq: STOK) is developing antisense oligonucleotide medicines that target RNA splicing to increase gene expression for the treatment of severe genetic diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Edward Kaye
Chief Medical Officer
Barry Ticho
Chief Operating Officer
Huw Nash
Vice President
Charles Allerson
Vice President
Isabel Aznarez
VP - R & D
Gene Liau
Browse more venture capital transactions:
Prev: 10/24/2018: Snappy venture capital transaction
Next: 10/24/2018: Bright Machines venture capital transaction
Share this article
Where The Data Comes From
We document all VC transactions involving tech companies. All VC database entries reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs